Pharma & Biotech Valuation

December 10, 2019

The purpose of this study is to provide corporate finance professionals, managers, and investors, an overview of valuation fundamentals employed in today’s pharmaceutical and biotech communities. These findings are relevant to understanding the values assigned by parties in negotiations for the acquisition or licensing of drug development programs and the approach in determining value.


This study is part of Gryphon Analytics’ public outreach program aimed at collecting and disseminating information about the important role that life sciences venture investing plays in driving revolutionary medical innovation.


Download the Gryphon Analytics Pharma & Biotech Report here:





Share on Facebook
Share on Twitter
Please reload

Featured Review

U.S. Healthcare Outlook

October 24, 2014

Please reload

Tag Cloud
Please reload

Gryphon Analytics Copyright 2012-2017

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey Google+ Icon